Li Z - Search Results

1

Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors.

Zhu Y, Zhao F, Li Z, Yu J. Zhu Y, et al. Among authors: li z. Cancer Manag Res. 2018 Aug 7;10:2475-2488. doi: 10.2147/CMAR.S167400. eCollection 2018. Cancer Manag Res. 2018. PMID: 30122997 Free PMC article. Review.

2

CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.

Zhu Y, Li M, Mu D, Kong L, Zhang J, Zhao F, Li Z, Liu X, Bo C, Yu J. Zhu Y, et al. Among authors: li z, li m. Oncotarget. 2016 Nov 1;7(44):71455-71465. doi: 10.18632/oncotarget.12213. Oncotarget. 2016. PMID: 27683115 Free PMC article.

3

Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma.

Zhu Y, Li M, Bo C, Liu X, Zhang J, Li Z, Zhao F, Kong L, Yu J. Zhu Y, et al. Among authors: li z, li m. Cancer Immunol Immunother. 2017 Mar;66(3):343-354. doi: 10.1007/s00262-016-1931-5. Epub 2016 Dec 3. Cancer Immunol Immunother. 2017. PMID: 27915370 Free PMC article.

4

Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo.

Zhu Y, Zang Y, Zhao F, Li Z, Zhang J, Fang L, Li M, Xing L, Xu Z, Yu J. Zhu Y, et al. Among authors: li z, li m. Am J Cancer Res. 2017 May 1;7(5):1198-1212. eCollection 2017. Am J Cancer Res. 2017. PMID: 28560067 Free PMC article.

5

The prognostic analysis of different metastatic patterns in extensive-stage small-cell lung cancer patients: a large population-based study.

Cai H, Wang H, Li Z, Lin J, Yu J. Cai H, et al. Among authors: li z. Future Oncol. 2018 Jun;14(14):1397-1407. doi: 10.2217/fon-2017-0706. Epub 2018 Jan 23. Future Oncol. 2018. PMID: 29359568

6

End-of-life chemotherapy is associated with poor survival and aggressive care in patients with small cell lung cancer.

Zhu Y, Tang K, Zhao F, Zang Y, Wang X, Li Z, Sun X, Yu J. Zhu Y, et al. Among authors: li z. J Cancer Res Clin Oncol. 2018 Aug;144(8):1591-1599. doi: 10.1007/s00432-018-2673-x. Epub 2018 May 29. J Cancer Res Clin Oncol. 2018. PMID: 29845418

7

PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study.

Shang X, Li Z, Lin J, Wang H, Wang Z. Shang X, et al. Among authors: li z. Cancer Manag Res. 2018 Sep 17;10:3561-3567. doi: 10.2147/CMAR.S173856. eCollection 2018. Cancer Manag Res. 2018. PMID: 30271204 Free PMC article.

8

GINS2 attenuates the development of lung cancer by inhibiting the STAT signaling pathway.

Sun D, Zong Y, Cheng J, Li Z, Xing L, Yu J. Sun D, et al. Among authors: li z. J Cancer. 2021 Jan 1;12(1):99-110. doi: 10.7150/jca.46744. eCollection 2021. J Cancer. 2021. PMID: 33391406 Free PMC article.

9

Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations.

Zhang Y, Wang W, Xu X, Li Y, Zhang H, Li J, Li Z. Zhang Y, et al. Among authors: li y, li j, li z. Cancer Manag Res. 2021 Apr 15;13:3293-3301. doi: 10.2147/CMAR.S299563. eCollection 2021. Cancer Manag Res. 2021. PMID: 33883942 Free PMC article.

10

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study.

Zhang C, Zhang C, Lin J, Li Z, Wang H. Zhang C, et al. Among authors: li z. JTO Clin Res Rep. 2020 Feb 11;1(1):100006. doi: 10.1016/j.jtocrr.2020.100006. eCollection 2020 Mar. JTO Clin Res Rep. 2020. PMID: 34589911 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

104,101 results

Search Page